Open original FDA record ↗Recall record
- FDA identifier
- Z-0751-2024
- Company in FDA record
- Randox Laboratories Ltd.
- FDA classification date
- Jan 18, 2024
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
There have been transcription errors on the Instructions For Use (IFU) of the Calibration Serum Level 3 (CAL2351 lot 1260UE, 1262UE and 1315UE) for target values of Bilirubin and Triglycerides, on the IFU of Human Assayed Multi-Sera Level 2 (HN1530) for TBIC taget value and on IFU of Human Assayed Multi-Sera Level 3 (HE 1532) for Lipase target value.
Source facts
- Action
- On November 20, 2023, the firm notified customers via Medical Device Correction letter. The letter consisted of three parts. This recall record covers the third part, which concerned transcription errors in the Instructions for Use (IFU) for the above listed products. Customers should discard all copies of the IFUs and download the latest versions from www.randox.com. Customers should discuss the contents of the recall notice with their Medical Director if they have used the incorrect target value for any of the affected products.
- Initiated
- 2023-11-13
- Root cause
- Under Investigation by firm
- Distribution
- US Nationwide distribution.
- Recall number
- Z-0751-2024
- Recall status
- Open, Classified
- CDRH record ID
- 204951
- FDA classified
- 2024-01-18
- Recall event number
- 93602